Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”

Abstract Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications—methadone, buprenorphine, and extended-release injectable naltrexone,— are efficacious for treating opioid use disorder (OUD). However, the utility of these medications is limited...

Полное описание

Библиографические подробности

Главные авторы:	Matisyahu Shulman, Roger Weiss, John Rotrosen, Patricia Novo, Elizabeth Costello, Edward V. Nunes
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2021-03-01
Серии:	Addiction Science & Clinical Practice
Предметы:	Opioid use disorder Buprenorphine Naltrexone Clinical trials
Online-ссылка:	https://doi.org/10.1186/s13722-021-00223-z
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!